Candriam S.C.A. Fate Therapeutics Inc Transaction History

Candriam S.C.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$21.04 - $36.06 $4.97 Million - $8.52 Million	236,403 Added 105.52%	460,436 $10.3 Million
Q2 2022 Aug 03, 2022	SELL	$17.78 - $42.39 $345,056 - $822,662	-19,407 Reduced 7.97%	224,033 $5.55 Million
Q1 2022 May 13, 2022	SELL	$29.67 - $60.28 $216,501 - $439,863	-7,297 Reduced 2.91%	243,440 $9.44 Million
Q2 2021 Jul 20, 2021	SELL	$67.25 - $92.52 $1.3 Million - $1.79 Million	-19,370 Reduced 7.17%	250,737 $21.8 Million
Q1 2021 Apr 29, 2021	SELL	$72.16 - $117.4 $288 - $469	-4 Reduced -0.0%	270,107 $23.6 Million
Q4 2020 Jan 22, 2021	BUY	$38.09 - $100.95 $10.3 Million - $27.3 Million	270,111 New	270,111 $24.6 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $161M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.